Landmark 10th Annual Awards Program Recognizes the Deseyne® Extended Depth of Focus (EDOF) contact lens as the “Best New Technology Solution – Ophthalmology” Worldwide BOCA RATON, Fla.–(BUSINESS WIRE)–#ContactLenses–The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that its Deseyne® daily disposable contact lens technology for … [Read more…]
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV. Pulse Biosciences’ Management is scheduled to present on Wednesday, May 13, at 4:35 pm PT. A live and recorded … [Read more…]
Solid Start to 2026 with Disciplined Execution Shareholder Value Creation BELO HORIZONTE, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the first quarter and three-month period ended March 31, 2026. Financial results … [Read more…]
LONDON–(BUSINESS WIRE)–Asset Value Investors Limited (“AVI”) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, “Rohto”), as a follow-up to its ongoing campaign, “Awakening Rohto”, launched last year and aimed at enhancing the company’s corporate value. AVI has published a detailed presentation on a dedicated website (www.AwakeningRohto.com). Since initiating … [Read more…]
— Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy — MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the publication of results from its FASTR randomized pilot study … [Read more…]
University of Michigan awards Ingeborg Hochmair an Honorary Doctor of Engineering Recognition for pioneering leadership at the intersection of engineering, healthcare, and accessibility Ingeborg Hochmair serves as Keynote Speaker at the 2026 Rackham Graduate Exercises, addressing graduate students INNSBRUCK, Austria & ANN ARBOR, Mich.–(BUSINESS WIRE)–Dr. Ingeborg Hochmair, co‑founder and CEO of MED‑EL, a global leader … [Read more…]
Initiative expands PMR resources with new patient-focused website and expert-led webinar to improve understanding, diagnosis, and care UPPER NYACK, N.Y.–(BUSINESS WIRE)–The Global Healthy Living Foundation (GHLF) announced the launch of a new patient-centered educational website and the release of a companion webinar designed to improve awareness, understanding, and management of polymyalgia rheumatica (PMR). Available at … [Read more…]
LONDON–(BUSINESS WIRE)–causaLens, a London-based AI scaleup, today announced the expansion of its strategic partnership with Syneos Health, a leading fully integrated biopharmaceutical solutions organization, to advance the industry’s shift toward faster, more intelligent and scalable commercialization. The companies initially partnered to execute advanced causal AI models to optimize commercial programs, pivoting from time-intensive data science … [Read more…]
“Turn down the food noise” TÜBINGEN, Germany–(BUSINESS WIRE)–#BariatricEndoscopy—During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 … [Read more…]
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the … [Read more…]
